Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab and Domvanalimab in Front-Line, PD-L1-High, Locally Advanced or Metastatic NSCLC
NCT04736173Phase 2Completed
- Sponsor
- Arcus Biosciences
- Start
- Feb 2021
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of domvanalimab, zimberelimab in non-small cell lung cancer (NSCLC), sponsored by Arcus Biosciences. Started Feb 2021; status: completed.
02
Drugs
domvanalimabzimberelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04736173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736173.